By comparing exhausted T-cell phenotypes in T1D and cancer, we can assess whether similar immunotherapy strategies can be applied to improve T1D therapy, such as enhancing exhausted T-cell reactivity through treatments targeting the PD-1/PD-L1 pathway. Here, PDCD1 is linked to type 1 diabetes mellitus.